Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apollomics Inc. - Warrant (NQ:APLMW)

0.0084 -0.0117 (-58.21%)
Streaming Delayed Price Updated: 3:58 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apollomics Inc. - Warrant

< Previous 1 2 Next >
Top movers in Thursday's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Thursday's session: top gainers and losers
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Let's take a look at the stocks that are in motion in today's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
What's going on in today's session
Here are the top movers in Monday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Traders are paying attention to the gapping stocks in Monday's session.
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Which stocks are experiencing notable movement on Monday?
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Top stock movements in today's session.
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
These stocks are gapping in today's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
Get insights into the top gainers and losers of Monday's pre-market session.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Gapping stocks in Thursday's session
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Top movers in Tuesday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Top stock movements in today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Here are the top movers in Monday's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
From Apollomics Inc.
Via GlobeNewswire
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
From Apollomics Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Monday's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From Apollomics Inc.
Via GlobeNewswire
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024 
From Apollomics Inc.
Via GlobeNewswire
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification 
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with... 
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need 
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations 
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Presentation at the 2024 BIO International Convention
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Private Placement Financing and Addition to Board of Directors
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
From Apollomics Inc.
Via GlobeNewswire
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR... 
From Apollomics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.